PT3677266T - Inibidor seletivo de egfr com mutação no exão 18 e/ou exão 21 - Google Patents
Inibidor seletivo de egfr com mutação no exão 18 e/ou exão 21Info
- Publication number
- PT3677266T PT3677266T PT188515555T PT18851555T PT3677266T PT 3677266 T PT3677266 T PT 3677266T PT 188515555 T PT188515555 T PT 188515555T PT 18851555 T PT18851555 T PT 18851555T PT 3677266 T PT3677266 T PT 3677266T
- Authority
- PT
- Portugal
- Prior art keywords
- exon
- mutation
- egfr inhibitor
- selective egfr
- selective
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017168606 | 2017-09-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT3677266T true PT3677266T (pt) | 2024-03-04 |
Family
ID=65527547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT188515555T PT3677266T (pt) | 2017-09-01 | 2018-08-31 | Inibidor seletivo de egfr com mutação no exão 18 e/ou exão 21 |
Country Status (23)
Country | Link |
---|---|
US (1) | US11701359B2 (pt) |
EP (1) | EP3677266B1 (pt) |
JP (1) | JP7065103B2 (pt) |
KR (1) | KR102676530B1 (pt) |
CN (2) | CN117159551A (pt) |
AU (1) | AU2018325819B2 (pt) |
BR (1) | BR112020004000A2 (pt) |
CA (2) | CA3074418C (pt) |
DK (1) | DK3677266T5 (pt) |
ES (1) | ES2972895T3 (pt) |
FI (1) | FI3677266T3 (pt) |
HU (1) | HUE066587T2 (pt) |
IL (1) | IL272929B2 (pt) |
JO (1) | JOP20200044A1 (pt) |
MX (1) | MX2020002296A (pt) |
MY (1) | MY199676A (pt) |
PH (1) | PH12020500419A1 (pt) |
PL (1) | PL3677266T3 (pt) |
PT (1) | PT3677266T (pt) |
SG (1) | SG11202001861WA (pt) |
TW (1) | TWI838345B (pt) |
WO (1) | WO2019045036A1 (pt) |
ZA (1) | ZA202001445B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
TWI838345B (zh) | 2017-09-01 | 2024-04-11 | 日商大鵬藥品工業股份有限公司 | 外顯子18及/或外顯子21突變型egfr之選擇性抑制劑 |
CN113423403B (zh) * | 2018-12-28 | 2025-02-18 | 大鹏药品工业株式会社 | 对l718和/或l792突变型治疗有抗性的egfr抑制剂 |
US20230372346A1 (en) * | 2020-09-08 | 2023-11-23 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
AU2022257621A1 (en) | 2021-04-13 | 2023-11-23 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
CN115785107B (zh) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
WO2025006697A1 (en) * | 2023-06-27 | 2025-01-02 | Taiho Pharmaceutical Co., Ltd. | Treatment methods for subjects with non-small cell lung cancer having an aberration in egfr |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
CA2601766A1 (en) | 2005-03-17 | 2006-09-28 | Novartis Ag | N- [3- (1-amin0-5, 6, 7, 8-tetrahydro-2 , 4, 4b-triazafluoren-9-yl)-phenyl] benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase |
ATE509624T1 (de) | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
US8779142B2 (en) | 2009-07-10 | 2014-07-15 | Taiho Pharmaceutical Co., Ltd. | Azabicyclo compound and salt thereof |
US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
EP2662357B1 (en) | 2011-01-07 | 2016-08-03 | Taiho Pharmaceutical Co., Ltd. | Bicyclic compounds or salts thereof for use in the treatment of cancer |
EP2762476A4 (en) | 2011-09-30 | 2015-03-25 | Taiho Pharmaceutical Co Ltd | 1,2,4-triazine-6-carboxamide derivative |
TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
WO2013125709A1 (ja) | 2012-02-23 | 2013-08-29 | 大鵬薬品工業株式会社 | キノリルピロロピリミジル縮合環化合物又はその塩 |
WO2014129596A1 (ja) | 2013-02-22 | 2014-08-28 | 大鵬薬品工業株式会社 | 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物 |
PT3037424T (pt) * | 2013-08-22 | 2017-12-18 | Taiho Pharmaceutical Co Ltd | Novo composto substituído com quinolina |
CN106687457B (zh) | 2014-05-13 | 2020-01-10 | 阿里亚德医药股份有限公司 | 用于激酶抑制的杂芳基化合物 |
CN110526912B (zh) | 2014-06-19 | 2023-02-14 | 武田药品工业株式会社 | 用于激酶抑制的杂芳基化合物 |
JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
TWI838345B (zh) | 2017-09-01 | 2024-04-11 | 日商大鵬藥品工業股份有限公司 | 外顯子18及/或外顯子21突變型egfr之選擇性抑制劑 |
-
2018
- 2018-08-31 TW TW107130585A patent/TWI838345B/zh active
- 2018-08-31 BR BR112020004000-2A patent/BR112020004000A2/pt unknown
- 2018-08-31 SG SG11202001861WA patent/SG11202001861WA/en unknown
- 2018-08-31 JO JOP/2020/0044A patent/JOP20200044A1/ar unknown
- 2018-08-31 IL IL272929A patent/IL272929B2/en unknown
- 2018-08-31 US US16/642,969 patent/US11701359B2/en active Active
- 2018-08-31 ES ES18851555T patent/ES2972895T3/es active Active
- 2018-08-31 CN CN202310869220.7A patent/CN117159551A/zh active Pending
- 2018-08-31 JP JP2019539655A patent/JP7065103B2/ja active Active
- 2018-08-31 MY MYPI2020001066A patent/MY199676A/en unknown
- 2018-08-31 CA CA3074418A patent/CA3074418C/en active Active
- 2018-08-31 PL PL18851555.5T patent/PL3677266T3/pl unknown
- 2018-08-31 FI FIEP18851555.5T patent/FI3677266T3/fi active
- 2018-08-31 PT PT188515555T patent/PT3677266T/pt unknown
- 2018-08-31 EP EP18851555.5A patent/EP3677266B1/en active Active
- 2018-08-31 DK DK18851555.5T patent/DK3677266T5/da active
- 2018-08-31 KR KR1020207008984A patent/KR102676530B1/ko active Active
- 2018-08-31 WO PCT/JP2018/032314 patent/WO2019045036A1/ja unknown
- 2018-08-31 HU HUE18851555A patent/HUE066587T2/hu unknown
- 2018-08-31 AU AU2018325819A patent/AU2018325819B2/en active Active
- 2018-08-31 MX MX2020002296A patent/MX2020002296A/es unknown
- 2018-08-31 CA CA3224526A patent/CA3224526A1/en active Pending
- 2018-08-31 CN CN201880064210.3A patent/CN111465397B/zh active Active
-
2020
- 2020-03-02 PH PH12020500419A patent/PH12020500419A1/en unknown
- 2020-03-06 ZA ZA2020/01445A patent/ZA202001445B/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT3677266T (pt) | Inibidor seletivo de egfr com mutação no exão 18 e/ou exão 21 | |
CY1119419T1 (el) | C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε) | |
EP3438284A4 (en) | Kit or device for detecting early stage pancreatic cancer or pancreatic cancer precursor lesions and detection method therefor | |
EP3417242A4 (en) | REAL-TIME RISK ASSESSMENT AND OPERATING CHANGES WITH SEMI-AUTOMATED VEHICLES | |
DK3411398T3 (da) | Målrettede terapeutiske midler og anvendelse heraf | |
EP3706801A4 (en) | Platinum complexes and uses thereof | |
EP2917371A4 (en) | METHOD FOR THE AGING PRESENTATION AND IDENTIFICATION OF AGENTS FOR PREVENTING AGE AGING | |
EP3663332C0 (en) | Detectable and multi detectable articles | |
RS63280B1 (sr) | Oksisteroli i postupci za njihovu upotrebu | |
EP3464597A4 (en) | OLIGONUCLEOTIDE PROBES AND USES THEREOF | |
EP3789506C0 (en) | MOLECULAR SNP MARKERS FROM HANGING PRUNUS MUME AND THEIR USE | |
IT201700035950A1 (it) | Simulatore per l’addestramento in ambienti confinati e/o sospetti di inquinamento | |
PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
PL3870775T3 (pl) | Panel, w szczególności panel podłogowy albo panel ścienny, i pokrycie panelowe | |
SI3290441T1 (sl) | RGMA-vezavni protein in njegova uporaba | |
EP3892184A4 (en) | DEVICE INTENDED TO AVOID EPISODES OF APNEA IN CHILDREN | |
IL247194A0 (en) | 1,2-substituted cyclopentanes as orexin receptor antagonists | |
EP3692330A4 (en) | BALL MEASUREMENT SYSTEM AND ASSOCIATED PROCESSES | |
FR3035569B1 (fr) | Article de bijouterie et/ou de joaillerie | |
EP3596740A4 (en) | METHODS AND APPARATUS FOR DETERMINING THE RESISTANCE OF A CABLE | |
EP3743525A4 (en) | PROXIMITY DETECTION METHODS AND COMPOSITIONS | |
ZA201705254B (en) | Block copolymers and the use thereof for improving the cold properties of fuels or combustibles | |
EP3640403A4 (en) | WORK VEHICLE AND SYSTEM INCLUDING A WORK VEHICLE | |
KR102067412B9 (ko) | 치매 평가 방법 및 이를 이용한 장치 | |
EP3766413A4 (en) | BIOCAPTEUR AND BIOCAPTEUR LAMINATE |